BioMedNewsBreaks

ThursdayApr 22, 2021 2:54 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Set to Start Potentially Pivotal Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP) is working to determine the efficacy of its lead drug candidate, Berubicin, for the treatment of glioblastoma multiforme (“GBM”), an aggressive type of brain cancer for which there is currently no cure. Promising results were demonstrated when another company completed a small Phase 1 trial well over a decade ago in which 44% of patients saw their disease stabilize or improve. One Berubicin patient was living cancer-free as of the most recent medical assessment in November, nearly 15 years after the Phase 1 trial (https://ibn.fm/JnFSS). “CNS now hopes to advance Berubicin to commercial production, with the…

Continue Reading

WednesdayApr 21, 2021 3:33 pm

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Achieves Critical Step Toward Commercial Sales of ‘Covid-ID Lab’

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced its entry into an agreement with an established German pharmaceutical wholesaler and service provider for the distribution, storage and logistics of XPhyto's diagnostic products in Germany. According to the update, the agreement secures XPhyto a full-service distribution partner for its 25-minute SARS-CoV-2 (COVID-19) RT-PCR test system ("Covid-ID Lab"). "With this agreement, we have secured a strong partner with an established medical distribution network throughout Germany. This is an exciting and critical step towards commercial sales of Covid-ID Lab," said Hugh Rogers, CEO and director of XPhyto. "The company's commercialization strategy…

Continue Reading

WednesdayApr 21, 2021 1:59 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Featured in Bell2Bell Podcast

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. Predictive Oncology’s newly appointed CEO, Mel Engle, its CFO, Bob Myers, and CTO of its Helomics subsidiary, Mark Collins, joined the latest episode to discuss updates on POAI’s financial footing, current operations and goals for 2021. “We are in a great situation, probably the best situation that we’ve been in since the existence of the company in terms of…

Continue Reading

WednesdayApr 21, 2021 10:07 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in CEO Roadshow Webinar Series

Genprex (NASDAQ: GNPX) CEO Rodney Varner will be a regular featured guest in an upcoming webinar series with CEO Roadshow. The series creates a weekly opportunity for Varner to provide weekly updates and highlight GNPX’s gene therapy pipeline in cancer and diabetes; in addition, Varner will answer questions following each week’s presentation. The webinar series is slated to run from April 22 through June 10, 2021, and will begin at 11 a.m. EDT; each presentation is scheduled to last 30 minutes. The company also noted that a recorded version of each webinar would be available on the company website as…

Continue Reading

WednesdayApr 21, 2021 9:30 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces Partnership to Offer Virtual Care for Patients with Diabetes

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, is partnering with MediOrbis, a telehealth provider specializing in chronic conditions, to provide remote patient monitoring services to Medicare patients with diabetes. The new virtual care initiative means that Medicare patients who have diabetes and who are eligible can receive convenient virtual care that is covered under their existing Medicare benefits. The telehealth services are delivered by MediOrbis with remote patient monitoring through DarioHealth's AI-powered digital chronic care platform. The announcement noted that the new virtual care program will be available to Dario's approximately 75,000 members with diabetes. Because…

Continue Reading

TuesdayApr 20, 2021 2:39 pm

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Expands Medical Board with Appointment of Triple-Certified Cardiologist

Healthy Extracts (OTCQB: HYEX), a leading developer and manufacturer of science-forward, clinically proven, plant-based and proprietary products for heart and brain health through its subsidiaries, BergametNA(TM) and Ultimate Brain Nutrients(TM), today announced that Dr. Joel Kahn, M.D., a world-renowned, triple board-certified cardiology specialist, has joined Healthy Extracts. According to the update, Dr. Kahn has utilized BergametNA Citrus Bergamot SuperFruit(TM) with thousands of patients and has seen positive cardiovascular benefits and arterial age reversal and flexibility. “We are so excited to welcome Dr. Joel Kahn, one of the few triple-certified cardiologists in the entire U.S., to our Medical Board,” said Duke…

Continue Reading

TuesdayApr 20, 2021 2:07 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Receives License of Year Award for Advances Made with Gene Therapy Program in Diabetes

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, was named the recipient of the first-ever License of the Year award presented from the University of Pittsburgh Innovation Institute (“UPII”). The award honors advances made with GNPX’s license from University of Pittsburgh toward progressing the development of its gene therapy for diabetes. GNPX has been involved in groundbreaking, potentially curative gene therapy shown to transform alpha cells in the pancreas into functional beta-like cells. The therapy, which involves the diabetes gene therapy candidate GPX-002, is potentially applicable to both type 1…

Continue Reading

TuesdayApr 20, 2021 9:49 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Appointment of New Global Positions

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has appointed two new positions at XP Diagnostics GmbH, its wholly owned German subsidiary. Wolfgang Probst will serve as the company’s new chief operations officer and Manfred Buchberger will be the new head of corporate development. An experienced management and finance consultant with impressive exposure to mergers and acquisitions, corporate re-organizations, and divestitures, Probst has a proven track record of leadership, strategic planning and organizational restructuring. In his new position, he will be responsible for managing the company's…

Continue Reading

TuesdayApr 20, 2021 9:34 am

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Collects 2b Disease Trial Data; Receives NASDAQ Notice Regarding Annual Report

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced collection of all patient data for its phase 2b Dupuytren’s disease trial, which was sponsored by the University of Oxford. The double-blind placebo-controlled trial involved 181 patients who were randomized across three sites, two in the United Kingdom and one in the Netherlands. While follow-up on the trial has been delayed by the COVID-19 pandemic, the company is now analyzing the information and has plans to announce top-line data in an upcoming…

Continue Reading

MondayApr 19, 2021 3:06 pm

BioMedNewsBreaks – GT Biopharma (NASDAQ: GTBP) Releases Q4, Year-End Results, Company Update

GT Biopharma (NASDAQ: GTBP), a clinical-stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (“NK”) cell engager, TriKE(TM) protein biologic technology platform, has released fourth-quarter and year-end financial and company results for the period ended Dec. 31, 2020. Company highlights noted in the announcement included entering into a GMP manufacturing partnership with Cytovance; the initiation of manufacturing of additional solid tumor TriKE for lung, breast, ovarian and gastrointestinal cancer programs in preparation for FDA clinical trials; and enhancing and expanding the company’s board of directors. In addition, the company completed a successful listing on NASDAQ…

Continue Reading